by CheckRare Staff and Ailene Cantelmi | Oct 8, 2026
On September 28th, the FDA approved Emcitate, or tiratricol, from Egetis Therapeutics. It’s the first-ever treatment for MCT8 deficiency, a condition also known as Allan-Herndon-Dudley syndrome. MCT8 deficiency is a rare genetic disorder that mostly affects...
by CheckRare Staff | Oct 1, 2026
October is Rett Syndrome Awareness Month. Rett syndrome is a neurodevelopmental condition that primarily affects girls. People with the disease appear to have normal psychomotor development during the first 6 to 18 months of life before developing severe problems with...
by CheckRare Staff | Sep 29, 2026
This week on The CheckRare Brief, we are joined by Eugene Lee, CMI Media Group’s Group President, Specialty Communications, for an industry perspective on some of the biggest developments in rare disease. New Rare Disease Center of Excellence CMI Media Group recently...
by CheckRare Staff | Sep 24, 2026
KAT6 syndromes are rare genetic neurodevelopmental disorders caused by genetic mutations in the KAT6A or KAT6B genes. KAT6 syndromes are characterized by speech and motor delay, low muscle tone, feeding or gastrointestinal issues, sleep challenges, and vision issues...
by CheckRare Staff | Sep 23, 2026
My name is Dr. Joshua Zeidner, and I’m a Professor of Medicine and Chief of Leukemia Research at the University of North Carolina Lineberger Cancer Center. I’m here today to raise awareness around an active global, phase 3, double-blind trial evaluating a combination...